451 related articles for article (PubMed ID: 27546100)
1. Steroid avoidance or withdrawal for kidney transplant recipients.
Haller MC; Royuela A; Nagler EV; Pascual J; Webster AC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD005632. PubMed ID: 27546100
[TBL] [Abstract][Full Text] [Related]
2. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients.
Montero N; Webster AC; Royuela A; Zamora J; Crespo Barrio M; Pascual J
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD007669. PubMed ID: 25220222
[TBL] [Abstract][Full Text] [Related]
3. Steroid avoidance or withdrawal for kidney transplant recipients.
Pascual J; Zamora J; Galeano C; Royuela A; Quereda C
Cochrane Database Syst Rev; 2009 Jan; (1):CD005632. PubMed ID: 19160257
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Karpe KM; Talaulikar GS; Walters GD
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.
Fairfield C; Penninga L; Powell J; Harrison EM; Wigmore SJ
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD007606. PubMed ID: 29630730
[TBL] [Abstract][Full Text] [Related]
8. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.
Fairfield C; Penninga L; Powell J; Harrison EM; Wigmore SJ
Cochrane Database Syst Rev; 2015 Dec; (12):CD007606. PubMed ID: 26666504
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
[TBL] [Abstract][Full Text] [Related]
11. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
12. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD010253. PubMed ID: 24901467
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive agents for treating IgA nephropathy.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
[TBL] [Abstract][Full Text] [Related]
14. Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipients.
Hong T; Zhang M; Fan J
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD009698. PubMed ID: 26457607
[TBL] [Abstract][Full Text] [Related]
15. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
Palmer SC; Navaneethan SD; Craig JC; Perkovic V; Johnson DW; Nigwekar SU; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD005019. PubMed ID: 24470059
[TBL] [Abstract][Full Text] [Related]
16. Interventions for preventing thrombosis in solid organ transplant recipients.
Surianarayanan V; Hoather TJ; Tingle SJ; Thompson ER; Hanley J; Wilson CH
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD011557. PubMed ID: 33720396
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Antibody induction versus corticosteroid induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010252. PubMed ID: 24880007
[TBL] [Abstract][Full Text] [Related]
19. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
